The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Subretinal Injection Techniques for Retinal Disease: A Review
Open accessAbstract
Inherited retinal dystrophies (IRDs) affect an estimated 1 in every 2000 people, this corresponding to nearly 2 million cases worldwide. Currently, 270 genes have been associated with IRDs, most of them altering the function of photoreceptors and retinal pigment epithelium. Gene therapy has been proposed as a potential tool for improving visual function in these patients. Clinical trials in animal models and humans have been successful in various types of IRDs. Recently, voretigene neparvovec (Luxturna®) has been approved by the US Food and Drug Administration for the treatment of biallelic mutations in the RPE65 gene. The current state of the art in gene therapy involves the delivery of various types of viral vectors into the subretinal space to effectively transduce diseased photoreceptors and retinal pigment epithelium. For this, subretinal injection is becoming increasingly popular among researchers and clinicians. To date, several approaches for subretinal injection have been described in the scientific literature, all of them effective in accessing the subretinal space. The growth and development of gene therapy give rise to the need for a standardized procedure for subretinal injection that ensures the efficacy and safety of this new approach to drug delivery. The goal of this review is to offer an insight into the current subretinal injection techniques and understand the key factors in the success of this procedure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The subretinal space is thought to be anatomically more closed and immune-privileged than the intravitreal space (Irigoyen et al., 2022).”
From AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery (2023) · cites this paper as Irigoyen et al., 2022
In the citing paper
“IVT injection potentially exposes the entire retina to gene therapy (Koponen et al., 2021; Puranen et al., 2022), whereas delivery to subretinal space allows direct contact of the vector with photoreceptors and the RPE layers (Irigoyen et al., 2022).”
From AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery (2023) · cites this paper as Irigoyen et al., 2022
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Schwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“The vector was injected using a 30G anterior chamber cannula through a pars plana approach [35].”
MethodMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
The molecular basis of human retinal and vitreoretinal diseases
Berger, W., Kloeckener‐Gruissem, B., & Neidhardt, J. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.03.004 · Cited by 609
Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector
Miyoshi, H., Takahashi, M., Gage, F. H., & Verma, I. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10319 · Cited by 497
Varela‐Fernández, R., Díaz-Tomé, V., Luaces-Rodríguez, A., Conde-Penedo, A., García‐Otero, X., Álvarez, A. L., Fernández‐Ferreiro, A., & Otero-Espinar, F. J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030269 · Cited by 374
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–106 of 106
SS-OCT-guided dual-arm master-slave robotic system for in vivo subretinal injection in porcine eyes
Wei, Z., Wang, Z., Chen, J., Huang, Y., Li, X., Wang, M., Gengwen, D. U., Yang, Y., Lin, C., & Yu, W. (2026) · Journal of Robotic Surgery · doi:10.1007/s11701-026-03912-6
Rashwan, R., Fuller-Carter, P. I., Lim, X. R., Brunet, A. A., Miller, A. L., Bhatt, Y., James, R., Anderson, D., Voigt, V., Paulo, J. A., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.09.025
Basics of Intraocular Pharmacotherapy
Melo, G. B., & Badaró, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-23052-2_17
Hsieh, M., Chen, Y.-J., Lai, H., Chun-chi, C., Chen, Y.-W., Ho, J. H., & TSAI, Y.-Y. (2026) · Research Square · doi:10.21203/rs.3.rs-11102886/v1
Physical Parameters Influencing the Rate of Subretinal Injection: A Microfluidic Analysis
Nagiel, A., & Rondoni, L. (2026) · Translational Vision Science & Technology · doi:10.1167/tvst.15.10.20
Ocular Gene Therapy in China: Technological Framework, Clinical Translation, and Future Perspectives
Zhang, D., He, Z., Lu, F., & Yang, Y. (2026) · Human Gene Therapy · doi:10.1177/10430342261495300
Metadata
- Authors
- Irigoyen, C., Amenabar Alonso, A., Sanchez-Molina, J., Rodríguez-Hidalgo, M., Lara-López, A., & Ruiz-Ederra, J.
- Affiliations
- University of the Basque Country (ES)
- Department of Ophthalmology, Donostia University Hospital (HUD), 20014 Donostia San-Sebastián, Spain
- Biogipuzkoa Health Research Institute (ES)
- Miramoon Pharma S.L., Avenida de Tolosa, 72, 20018 San Sebastián, Spain
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-08-12
- Volume
- 11
- Issue
- 16
- Pages
- 4717
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC9409835
- OpenAlex
- W4291465575
- Cited by
- 106
- References
- 88
- Citations by year
- 2026: 28 · 2025: 45 · 2024: 17 · 2023: 16
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Health Carlos III (PI20/01186, PTQ2019-010412, DIN2020-011302)
- European Regional Development Fund (Institute of Health Carlos III/ISCIII) (PI20/01186, PTQ2019-010412, DIN2020-011302)
- Retinitis Pigmentosa Patients of Gipuzkoa Foundation (BEGISARE) (PI20/01186, PTQ2019-010412, DIN2020-011302)
- Spanish Ministry of Science and Innovation (PI20/01186, PTQ2019-010412, DIN2020-011302)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- subretinal injection, retinal gene therapy, inherited retinal disease, RPE65, voretigene neparvovec, viral vectors, photoreceptors, retinal pigment epithelium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
